Craig Coleman
Professor/Pharmacy Practice
Storrs Mansfield
Are you Craig Coleman?
How to update your information.
Scholarly Contributions
620 Scholarly Contributions
Impact of Differences in Once- vs Twice-Daily Medications Adherence on the Risk of Bleed and Stroke in Non-Valvular Atrial Fibrillation: Analysis of Randomized Trials and Claims Data Sources
2017
Research Type: Poster/Presentation
Effectiveness and Safety of Apixaban and Rivaroxaban Versus Warfarin for the Secondary Prevention of Stroke or Systemic Embolism Among Nonvalvular Atrial Fibrillation Patients
2017
Research Type: Poster/Presentation
REAL-WORLD EVIDENCE OF STROKE PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE UNITED STATES: THE REVISIT-US STUDY
2017
Research Type: Poster/Presentation
Importance of Balanced Follow-up Time and Other Study Design Considerations When Evaluating Adherence Using Two Novel Oral Anticoagulants
2017
Research Type: Poster/Presentation
External validation of a multivariable claims-based prediction rule for in-hospital pulmonary embolism mortality
2017
Research Type: Poster/Presentation
“Advantages of Once Daily Dosing on Medication Adherence and Persistence”.
2017
Research Type: Poster/Presentation
The Association Between Comorbid Atrial Fibrillation and the Type of Coronary Stent Implanted in Acute Coronary Syndrome Patients.
2017
Research Type: Poster/Presentation
Outcomes Related to Variation in Hospital Pulmonary Embolism Observation Stay Utilization
2016
Research Type: Poster/Presentation
Abstract 13112: Benefit of Early Discharge Among Patients With Low-risk Pulmonary Embolism: Focus on Net Clinical Impact
2016
Research Type: Poster/Presentation
External Validation of Prognostic Rules for 30-Day Post-Pulmonary Embolism Mortality: Assessment of a Claims-Based and Three Clinical-Based Approaches
2016
Research Type: Poster/Presentation
Impact of Dosing Frequency on Adherence to Chronic Cardiovascular Medications: A Meta-Regression Analysis
2016
Research Type: Poster/Presentation
External Validation of Generic and Cancer-Specific Risk Stratification Criteria for Predicting 30-Day Mortality in Patients Presenting with Pulmonary Embolism and Active Cancer
2016
Research Type: Poster/Presentation
External Validation of a Clinical and Claims-Based Approach for Predicting 90-Day Post-Pulmonary Embolism Outcomes Among US Veterans
2016
Research Type: Poster/Presentation
Is rivaroxaban associated with shorter hospital stays and reduced costs versus parenteral bridging to warfarin among patients with pulmonary embolism?
2016
Research Type: Poster/Presentation
Association Between Weekend Admission for Atrial Fibrillation or Flutter and In-hospital Mortality, Procedure Utilization, Length-of-stay and Treatment Costs
2016
Research Type: Poster/Presentation
Improved Treatment Satisfaction Independent of Stroke and Bleeding Risk Among Patients Transitioned From a Vitamin K Antagonist to Rivaroxaban: A XANTUS-ACTS Analysis
2016
Research Type: Poster/Presentation
Real-world evidence of stroke prevention in patients with non-valvular atrial fibrillation in the United States: the REVISIT-US study
2016
Research Type: Poster/Presentation
External Validation of the Hesta Criteria for Identifying Acute Pulmonary Embolism Patients at Low-Risk of Early Mortality
2016
Research Type: Poster/Presentation
Adherence to Rivaroxaban and Dabigatran in Nonvalvular Atrial Fibrillation Patients in the United States
2016
Research Type: Poster/Presentation